Henry Ford Health System Henry Ford Health System Scholarly Commons

Basic Science Research

Medical Education Research Forum 2019

5-2019

Rare Histological Variants of Prostate Adenocarcinoma (PCa): NCDB Analysis

Sohrab Arora Henry Ford Health System

Chandler Bronkema

Akshay Sood Henry Ford Health System

Deepansh Dalela Henry Ford Health System

Jacob Keeley Henry Ford Health System

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/merf2019basicsci

Recommended Citation

Arora, Sohrab; Bronkema, Chandler; Sood, Akshay; Dalela, Deepansh; Keeley, Jacob; Menon, Mani; and Abdollah, Firas, "Rare Histological Variants of Prostate Adenocarcinoma (PCa): NCDB Analysis" (2019). *Basic Science Research*. 4.

https://scholarlycommons.henryford.com/merf2019basicsci/4

This Poster is brought to you for free and open access by the Medical Education Research Forum 2019 at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Basic Science Research by an authorized administrator of Henry Ford Health System Scholarly Commons.

Authors

Sohrab Arora, Chandler Bronkema, Akshay Sood, Deepansh Dalela, Jacob Keeley, Mani Menon, and Firas Abdollah







Rare histological variants of prostate adenocarcinoma (PCa): A National Cancer Database (NCDB) analysis

Sohrab Arora, MD, MS, MCh ^{a*}, Chandler Bronkema^b, Akshay Sood, MD ^a, Deepansh Dalela, MD ^a, Jacob Keeley, MS ^a, Mani Menon, MD ^a, Firas Abdollah, MD, FEBU ^a

> ^a Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA ^bWayne state university school of medicine, Detroit, MI, USA

Rare histological variants of prostate adenocarcinoma (PCa): A National Cancer Database (NCDB) analysis.

Introduction

- American Joint Committee on Cancer (AJCC) recognizes five rare histological variants of PCa.
- Several single institution studies describing the presentation and overall survival (OS) of these variants exist.
- Contemporary national data is lacking.
- Our aim was to describe the contemporary presentation and overall survival of these rare variants of prostate adenocarcinoma.

Rare histological variants of prostate adenocarcinoma (PCa): A National Cancer Database (NCDB) analysis.


Materials and Methods

- From 2004-2015, we selected cases of mucinous, ductal, signet ring cell (SRC), adenosquamous, and neuroendocrine (NEC) variants of PCa from the National Cancer Database.
- Characteristics at presentation for each variant were compared with nonvariant PCa.
- Cox regression was used to study the effect of histological subtype on overall mortality.


Rare histological variants of prostate adenocarcinoma (PCa): A National Cancer Database (NCDB) analysis.


Results

- <1 percent (0.38%) of patients presented with rare-variant PCa.
- All variants had a higher clinical T stage at presentation than nonvariant PCa.
- Metastatic disease was most common with NEC (62.9%), followed by adenosquamous (31.1%), SRC (10.3%), and ductal (9.8%) variants, compared to 4.2% in nonvariant PCa.
- Metastatic disease in mucinous was similar to nonvariant PCa (p = 0.15).
- SRC, mucinous, and ductal variants presented with a significantly higher PSA and higher biopsy grade.
- Estimated 5-year OS was highest in mucinous variant (89.3%), followed by nonvariant (87.2%), ductal (76.4%), SRC (67.0%), adenosquamous (20.5%), and NEC PCa (13.4%).
- Variant histology was an independent predictor of mortality on cox regression.




*All p<0.001 except mucinous (p=0.15)





*SRC, mucinous, and ductal variants presented with significantly higher PSA (all p < 0.001)



Conclusions

- There are differences in the presentation and OS among rare variants of PCa.
- NEC, adenosquamous, SRC, and ductal variants more commonly present with metastatic disease.
- All variants present with a higher local stage than nonvariant PCa.
- NEC variant is associated with the worst, and mucinous variant with the best OS.

- Won the best poster prize at EAU Barcelona
- Being presented at AUA Chicago as we speak